Achieving 20% Revenue Growth
First written in FY2021. 3 of 14 entries say "Advanced", first in FY2023-Q1. Latest entry: FY2027-H1.
The whole theme swung hardest in 2018: 2 of 6 companies on the "Worse" side.
4 other companies' latest entry also says "Other".
- FY2027-H1Continued interim sales growthAnnual report
「As a result, sales for the interim consolidated accounting period were ¥4,935 million, up 18.9% year on year.」
Interim sales increased 18.9% year on year. Although the growth rate declined from 22.1% in the previous interim period, the sales growth trend has continued. The disclosure does not specify how this relates to the previous 20% sales growth target or whether the current target has been changed. - FY2026Full-year revenue growth recoveryAnnual report
「Company-wide revenue was ¥10,040 million, up 19.6% year on year.」
Revenue increased 19.6% year on year, with the full-year growth rate recovering from the 2.3% increase in the previous interim period. Revenue growth had already been reframed within a metric framework focused on profitability and efficiency, and its relationship with the previous 20% target was not specified. - FY2026-H1Interim revenue growth recoversAnnual report
「As a result, revenue for the interim consolidated accounting period was ¥4,151 million, up 22.1% year on year.」
Revenue for the interim consolidated accounting period increased 22.1% year on year, with the growth rate recovering from the 2.3% increase in the previous interim period. Revenue growth had already been reframed within a metric framework focused on profitability and efficiency, and its relationship with the previous 20% target was not specified. - FY2025-H1Low interim revenue growthAnnual report
「As a result, revenue for the interim consolidated accounting period was ¥3,398 million, up 2.3% year on year.」
Revenue growth for the interim consolidated accounting period was 2.3%, below the previous 20% growth target. The metric framework had been reframed in the previous fiscal year to focus on profitability and efficiency. - FY2025-Q1Low revenue growthAnnual report
「As a result, revenue for the cumulative consolidated first quarter was ¥1,388 million, up 2.1% year on year.」
On a consolidated basis, revenue increased 2.1% year on year. This was well below the previous 20% revenue growth target, although the target had been reframed in the previous fiscal year within a metric framework focused on profitability and efficiency. - FY2024ReframedAnnual report
「The Company has previously focused on revenue growth and operating margin as key metrics in pursuing growth in scale. Going forward, it will place greater emphasis on profitability and efficiency, adding EBITDA margin as a new key management metric alongside the existing metric of operating margin.」
The Company is shifting from its previous emphasis on revenue growth to a management-metric framework focused on profitability and efficiency. - FY2024-Q3Sales remain soft; forecast missedAnnual report
「As a result, revenue for the cumulative consolidated third quarter was ¥4,693 million, operating loss was ¥631 million, ordinary loss was ¥519 million, and net loss attributable to owners of the parent was ¥455 million.」
Revenue remained soft and fell below the initial forecast in the Healthcare Business and New Business Areas. As this was the first year of consolidation, no year-on-year comparison was provided, and the relationship with the 20% revenue growth target was not specified. - FY2024-Q2Sales remain softAnnual report
「Against this backdrop, the impact of global economic trends on the Group's cumulative consolidated results for the second quarter was limited, but revenue remained somewhat soft, as it had in the first quarter.」
Revenue was described as somewhat soft for a second consecutive quarter. As this was the first year of consolidation, no year-on-year comparison was provided, and the relationship with the 20% growth target was not specified. - FY2024-Q1Quarterly performance softensAnnual report
「As a result, revenue for the cumulative first quarter was ¥1,359 million, operating loss was ¥48 million, ordinary income was ¥69 million, and net income attributable to owners of the parent was ¥39 million.」
The first quarter got off to a somewhat weak start, with revenue slightly lower year on year. Because consolidated accounting began during the quarter, no comparative analysis was conducted against the same period of the previous year or the previous consolidated fiscal year, and the relationship with the previous 20% revenue growth target was not specified. - FY2023-Q3AdvancedAnnual report
「As a result, revenue for the cumulative third quarter was ¥4,421 million, up 23.7% year on year」
Revenue growth for the cumulative third quarter was 23.7%, remaining above the previous 20% target. - FY2023-Q2AdvancedAnnual report
「As a result, revenue for the cumulative second quarter was ¥2,961 million, up 20.7% year on year」
Revenue for the cumulative second quarter increased 20.7% year on year, exceeding the previously stated 20% revenue growth target. However, this filing does not explicitly state that the target was achieved. - FY2023-Q1AdvancedAnnual report
「As a result, revenue for the cumulative first quarter was ¥1,419 million, up 23.0% year on year」
First-quarter revenue increased 23.0% year on year. Although quarterly results exceeded the previously stated 20% target, this filing does not explicitly state that the target was achieved. - FY2022AchievedAnnual report
「The company exceeded its management target of 20% year-on-year revenue growth by 13.3 percentage points. It will continue working to clear the target from the next fiscal year onward.」
Revenue growth was 32.9%, exceeding and achieving the 20% target by 13.3 percentage points. - FY2021First statedAnnual report
「Although the company fell 3.2 percentage points short of its management target of 20% year-on-year revenue growth, it will further strengthen its efforts to achieve the target from the next fiscal year onward.」
The company states that revenue growth for the period was 16.8%, 3.2 percentage points below its stated target of 20%.